Fapon Biopharma Unveils Safer Cancer Immunotherapy

SAN DIEGO, June 3, 2024 — During the Bio International Convention 2024 held from June 3-6 in San Diego, Fapon Biopharma, a leader in therapeutic antibodies and fusion proteins, introduced a novel immunocytokine named FP008. This innovative fusion protein merges a modified IL-10M with an anti-PD-1 antibody, offering a potential breakthrough treatment for solid tumors resistant to existing anti-PD-1 therapies. This announcement underscores Fapon Biopharma's expertise in developing advanced cancer treatments.

FP008 is an inventive drug candidate, pending patent approval, that leverages sophisticated antibody technologies. As a unique biologic, it combines IL-10M, an altered IL-10 monomer variant, with an anti-PD-1 antibody. This combination aims to enhance therapeutic effectiveness while mitigating the high toxicity typically associated with wild-type IL-10. FP008 represents a significant milestone in cancer treatment by reducing the apoptosis of exhausted CD8+ T cells and reviving their activity in laboratory settings. Additionally, it effectively increases CD8+ T cell levels in the tumor microenvironment, showcasing a strong anti-tumor impact in live models. The drug demonstrated favorable properties and was well-tolerated in toxicity tests conducted on cynomolgus monkeys at doses up to 10 mg per kg. Consequently, FP008 emerges as a promising candidate for further development.

The introduction of FP008 could revolutionize immunotherapy for cancer patients who do not respond to current treatments. Fapon Biopharma aims to present this therapeutic option to a global audience and seek partners to further its development, ultimately benefiting cancer patients worldwide.

Fapon Biopharma plans to file an Investigational New Drug (IND) application for FP008 with the FDA in early 2025. The company remains dedicated to creating more effective and accessible treatments through continual innovation and collaborative efforts.

Fapon Biopharma focuses on discovering and developing biologics to treat cancers, autoimmune disorders, and other conditions with unmet medical needs. By leveraging advanced technologies, Fapon Biopharma has established state-of-the-art drug discovery platforms, including a pioneering antibody discovery platform utilizing mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a distinct pipeline of leading drug candidates, Fapon Biopharma possesses comprehensive capabilities that encompass the entire drug development process, from discovery and preclinical research to Chemistry, Manufacturing, and Controls (CMC) and early clinical development. Committed to innovation, Fapon Biopharma strives to deliver safer, more efficacious, affordable, and accessible biologics for everyone.

This breakthrough highlights Fapon Biopharma's ongoing commitment to addressing unmet medical needs through innovative solutions. As FP008 progresses towards clinical trials, the potential for improved cancer therapies becomes increasingly promising, offering hope to patients globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!